ASCO 2023 | Sub-analysis of STAMP trial: ctDNA as predictive biomarker for CCA monitoring during ACT

Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Korea, provides an overview of a sub-analysis of the randomized Phase II STAMP (NCT03079427) trial on the utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients (pts) with cholangiocarcinoma (CCA) before and during adjuvant chemotherapy (ACT). A cohort of 89 CCA patients post-surgery was analyzed using a personalized ctDNA assay at three time points: baseline, after 5 cycles of treatment, and after 8 cycles of treatment. Results showed that ctDNA-positive patients at baseline had a trend towards shorter recurrence-free survival (RFS) compared to ctDNA-negative patients. Furthermore, patients who remained ctDNA-positive during treatment had significantly shorter RFS. The primary tumor site or type of adjuvant chemotherapy did not affect RFS. In multivariate analysis, positive ctDNA status at baseline remained significant for poor RFS. This study suggests that ctDNA monitoring could help optimize clinical decision-making for patients with resected CCA, although further validation through larger prospective studies is needed. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.